RxDoctor Payments Data

Andrew Corbin

Psychiatric/Mental Health · Lincoln, NENPI 1871078501

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 76 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$248
  • E.r. Squibb & Sons, L.L.C.$210
  • AbbVie$199
  • Alkermes, Inc.$197
  • Lundbeck LLC$195
  • Johnson & Johnson$153
  • plus $518 from 11 others

What the payments were for

  • Food & beverage$1,721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,721 in reported general payments places this provider in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$24,641
Medicare patients
73
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate122$439,659
Invega TrinzaPaliperidone Palmitate25$254,191
Abilify MaintenaAripiprazole43$115,730
AustedoDeutetrabenazine14$73,861
VraylarCariprazine Hcl32$42,897
AristadaAripiprazole Lauroxil13$42,088
CaplytaLumateperone Tosylate19$34,104
LybalviOlanzapine/Samidorphan Malate12$25,697
RexultiBrexpiprazole17$24,115
Clozapine OdtClozapine21$19,195
Divalproex Sodium ErDivalproex Sodium177$19,053
Paliperidone ErPaliperidone110$18,574
TrintellixVortioxetine Hydrobromide32$14,754
Ziprasidone Hcl118$14,750
FanaptIloperidone12$12,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$153$693,850147 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$55$139,84460 claims
Teva Pharmaceuticals USA, Inc.Austedo$87$73,86114 claims
Alkermes, Inc.Aristada, Lybalvi$197$67,78625 claims
AbbVieVraylar$199$42,89732 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$248$34,10419 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$59$26,61360 claims
Axsome Therapeutics, Inc.Auvelity$39$6,77711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →